Sidekick Health

Sidekick Health is a digital therapeutics company focused on developing personalized programs for individuals dealing with multiple chronic conditions, delivered via a smartphone app. These programs include atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, NASH, congestive heart failure, breast cancer and high risk maternity. It claims that its members are thrice as likely to achieve a 5% weight loss goal using its program and that it has 30% higher program adherence than standard care.

Its app-based software combines AI and gamified measures to reward lifestyle changes and also delivers personalized recommendations aimed at improving health outcomes. The firm also provides disease-specific educational content.

As of June 2024, it has served over 75,000 patients by over 13,000 healthcare providers across the US, Germany, Sweden, and Iceland. Meanwhile, its platform has collected more than 50 million data points that can provide deeper insight into behavioral trends.

In October 2023, the company acquired aidhere for an undisclosed amount to strengthen its position in the digital therapeutics space and expand its offerings to payer partners in the US. The company also acquired PINK! to expand into oncology and women's health in June 2024.

Key customers and partnerships

The firm operates a B2B2C business model, partnering with big pharma to develop complementary digital programs which can be used together with prescription medication. The firm has a partnership with Bayer for peripheral artery disease, Eli Lilly for breast cancer, as well as collaborations with Pfizer for treating five inflammatory conditions and eczema. It also works with insurance providers, such as Anthem, to offer concierge services for individuals with Crohn’s disease and Covid-19, allowing them to track their symptoms daily.

Funding and financials

In May 2022, the company completed a USD 55 million Series B funding round led by Novator Ventures. The funds were invested in expanding its chronic disease treatment programs, forming new partnerships, and enhancing existing ties with players in the healthcare and pharmaceutical industry. Additionally, the company planned to double its headcount to 240 team members.

In June 2024, the company had grown at 80% CAGR.